Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 10/20 | 0.55 |
| ▸ | CA2 | P00918 | 9/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.55 |
| ▸ | CA1 | P00915 | 9/20 | 0.49 |
| ▸ | CA7 | P43166 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 6/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23762328 | 0.86 | TDP1 (0.61) | CA12CA2CA14CA1CA7 | |
| SCHEMBL23762313 | 0.84 | TDP1 (0.58) | CA12CA2CA14CA1CA7 | |
| SCHEMBL22398423 | 0.84 | CA12 (0.57) | CA12CA2CA14CA1CA7 | |
| SCHEMBL5332844 | 0.84 | CA12 (0.54) | CA12CA2CA14CA1CA7 | |
| SCHEMBL22404329 | 0.83 | CA12 (0.59) | CA12CA2CA14CA1CA7 | |
| SCHEMBL23762491 | 0.83 | CA12 (0.59) | CA12CA2CA14CA1CA7 | |
| SCHEMBL5332706 | 0.82 | CA12 (0.64) | CA12CA2CA14CA1CA7 | |
| SCHEMBL15419987 | 0.81 | CA12 (0.58) | CA12CA2CA14CA1CA7 | |
| SCHEMBL22404312 | 0.80 | CA12 (0.60) | CA12CA2CA14CA1CA7 | |
| SCHEMBL20646495 | 0.79 | CA12 (0.63) | CA12CA2CA14CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10335411-B2 | Administration of ubiquitin-activating enzyme inhibitor and radiation | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180133221-A1 | ADMINISTRATION OF UBIQUITIN-ACTIVATING ENZYME INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | MILLENNIUM PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20170333434-A1 | ADMINISTRATION OF UBIQUITIN-ACTIVATING ENZYME INHIBITOR AND RADIATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333434-A1 | ADMINISTRATION OF UBIQUITIN-ACTIVATING ENZYME INHIBITOR AND RADIATION | UBE2E1, UBA1, USP1 | CA12 2487/4885CA2 2594/4885CA14 1190/4885 |
| US-10335411-B2 | Administration of ubiquitin-activating enzyme inhibitor and radiation | UBE2E1, UBA1, USP1 | CA12 2487/4885CA2 2594/4885CA14 1190/4885 |
| US-20180133221-A1 | ADMINISTRATION OF UBIQUITIN-ACTIVATING ENZYME INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | USP1, UBA1, UBE2E1 | CA12 2882/4885CA2 2480/4885CA14 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.